Press Releases
QIAGEN Adopts GNS Healthcare’s Gemini – The in silico Patient™ Across Multiple Cancers
Partnership enables enhanced capability to discover new targets and prognostic markers Somerville, MA: GNS Healthcare, the leading AI-driven precision medicine company, today announced a partnership with QIAGEN, the leading global provider of Sample to Insight...
read moreGNS Healthcare Presents Novel Use of AI to Identify Drivers of Response to Immune Checkpoint Inhibitor Therapy
AI-driven in silico patients used to accurately identify types of immune responses in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). CAMBRIDGE, Mass.– [July 21, 2020] – GNS Healthcare (GNS), a leading AI and simulation company,...
read moreGNS Healthcare Launches Gemini, the First In Silico Patient for Multiple Myeloma
A transformative innovation GeminiTM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma GNS Healthcare, an AI-driven precision medicine company, today announced the launch of...
read moreGNS Healthcare Launches Gemini, the First In Silico Patient for Multiple Myeloma
A transformative innovation GeminiTM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma GNS Healthcare, an AI-driven precision medicine company, today announced the launch of...
read moreGNS Healthcare and Multiple Myeloma Research Foundation (MMRF) Announce a Five-Year Collaboration to Advance Precision Medicine
Partnership Aims to Answer Key Questions in Multiple Myeloma Patient Care and Accelerate Discovery and Development of New Treatments Cambridge, MA – June 18, 2020-- GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) today announced a five-year...
read moreGNS Healthcare and Collaborators Identify PHF19 as Marker of Aggressive Multiple Myeloma Progression
Study results are from the DREAM Challenge and are published in Leukemia CAMBRIDGE, Mass.– May 28, 2020 – GNS Healthcare (GNS), a leading AI-driven precision medicine, announced results of a recently published collaboration that uncovered transcription factor PHF19 as...
read moreIndustry Luminaries Across Biopharmaceuticals, Payers, and Technology Convene on GNS Healthcare’s In Silico Patient Advisory Board
Michael Bonney, Tom Daniel, Peter Neupert, and Lee Newcomer join GNS Healthcare’s in silico Patient Advisory Board Cambridge, MA – April 21, 2020 – GNS Healthcare, an AI-driven precision medicine company, is pleased to announce the formation of its in silico Patient...
read moreIndustry Luminaries Across Biopharmaceuticals, Payers, and Technology Convene on GNS Healthcare’s In Silico Patient Advisory Board
Michael Bonney, Tom Daniel, Peter Neupert, and Lee Newcomer join GNS Healthcare’s in silico Patient Advisory Board Cambridge, MA – April 21, 2020 – GNS Healthcare, an AI-driven precision medicine company, is pleased to announce the formation of its in silico Patient...
read moreGNS Healthcare Welcomes Earl Steinberg as Chief of Health Plan Division
CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant...
read moreGNS Healthcare Announces Strategic Investment from Merck Global Health Innovation Fund
Merck GHI joins leading biopharma companies Amgen, BMS, Zambon Pharmaceuticals, and leading health plans Cigna, Cambia Health Solutions, Echo Health Ventures, Horizon Blue Cross of NJ, and Heritage Provider Network, as an investor in GNS Healthcare. CAMBRIDGE, Mass. –...
read more